---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000067"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:33:08.170453+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Nurix Therapeutics annual meeting elects directors, ratifies auditor, passes say-on-pay

## Summary
- All three Class II director nominees elected: Reinsdorf (43.57M for), Saltzman (50.30M for), Baynes (60.82M for).
- Ratification of PricewaterhouseCoopers as independent auditor for FY2025 approved (64,950,599 for, 85,040 against).
- Non-binding advisory vote on named executive officer compensation passed (49,788,975 for, 11,341,365 against).
- Annual meeting held May 19, 2025; 65,056,197 shares (85.33% of voting power) constituted a quorum.

## SEC filing metadata
- accession: 0001549595-25-000067
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000067/0001549595-25-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000067/nrix-20250519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000067
- JSON: https://secwatch.observer/filing/0001549595-25-000067.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.